Kopetz S, Grothey A, Yaeger R, et al. - Via an open-label, phase 3 trial of 665 individuals with BRAF V600E–mutated metastatic colorectal cancer who had had disease progression following one or two former regimens, researchers ascertained the role of encorafenib, binimetinib, and cetuximab (triple therapy) in BRAF V600E–mutated colorectal cancer. In the triplet-therapy group, the validated response rate was 26%. In individuals with metastatic colorectal cancer with the BRAF V600E mutation, a combination of encorafenib, cetuximab, and binimetinib led to significantly prolonged overall survival and a greater response rate compared with standard therapy.